Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

NCT01480479 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01480479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01480479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma
Lead sponsor
Celldex Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
November 30, 2016
Enrollment
745 (actual)
Sites
223

Conditions

As the registry lists them; a condition with its own page is linked.

giant cell glioblastoma, glioblastoma, glioblastoma with oligodendroglial component, gliosarcoma, small cell glioblastoma